August 22, 2005 02:02 ET

Statement re MVA

Cambridge, UK -- (MARKET WIRE) -- August 22, 2005 --Statement re MVA

Cambridge, UK and Cambridge, Massachusetts - 22 August 2005 - Acambis plc ("Acambis") (LSE: ACM, NASDAQ: ACAM) Acambis notes the press release issued by Bavarian Nordic A/S ("BN") after the market close on Friday, 19 August. In that, BN said that it had filed two legal actions against Acambis in the US, in relation to the intellectual property on its MVA smallpox vaccine.

Acambis has not yet received a copy of the legal claims, so is unable to comment on any of the specifics. However, based on the information in BN's press release, Acambis believes the claims are without foundation. To the extent that it is required to do so, Acambis will be vigorously defending its legal position.

Gordon Cameron, Acambis' Chief Executive Officer, commented:

"We have always maintained, having consulted throughout with external patent counsel, that we have freedom to research, develop, manufacture and sell our MVA vaccine candidate. That position still stands and we do not expect either of the BN legal actions to affect that position, in particular for the current US Government tender process, for which a Request for Proposals was issued last week. We continue to believe that we are very well positioned to win an award under that process."



Gordon Cameron, Chief Executive Officer: Tel +1 (617) 761 4200
David Lawrence, Chief Financial Officer: Tel +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor Relations: Tel +44 (0) 1223 275

Financial Dynamics:
David Yates/Lucy Briggs: Tel +44 (0) 20 7831 3113

About Acambis

Acambis is a leading developer of vaccines to prevent and treat infectious diseases. Recognised internationally as the leading producer of smallpox vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000, and is manufacturing emergency-use stockpiles of this investigational vaccine for the US Government and other governments around the world. It is also developing an attenuated smallpox vaccine, MVA3000, under contracts with the US National Institutes of Health. Acambis is establishing a travel vaccines franchise through its US-based subsidiary Berna Products Corporation, which markets Vivotif®, the world's only licensed oral typhoid vaccine, in North America. Acambis has other potential travel vaccines in development and is also developing an investigational vaccine against the West Nile virus, which has spread to 48 US States in the last six years.

Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary listing is on the London Stock Exchange (ACM) and its shares are listed in the form of American Depositary Receipts on NASDAQ (ACAM). More information is available at

About Acambis' NIAID contracts

Acambis has been awarded two contracts by the NIAID for the manufacture and development of its MVA smallpox vaccine, MVA3000. The first contract, awarded in February 2003, was for $9.2m. The second, awarded in September 2004, has a $76m core component requiring clinical testing and manufacture of 500,000 doses of MVA3000, and an optional element potentially worth $55m for the manufacture of a further 2.5 million doses of MVA3000. Acambis is co-developing MVA3000 with Baxter Healthcare SA ("Baxter"), which is providing process development and manufacturing services.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties, including the timing and results of clinical trials, product development, manufacturing and commercialisation risks, the risks of satisfying the regulatory approval process in a timely manner, the need for and the availability of additional capital. For a discussion of these and other risks and uncertainties see "Risk management" in the Company's 2004 Annual Report and 2004 Form 20-F, in addition to those detailed on the Company's website and in the Company's filings made with the Securities and Exchange Commission from time to time. These forward-looking statements are based on estimates and assumptions made by the management of Acambis and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements.

                      This information is provided by RNS
            The company news service from the London Stock Exchange